# Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

> **NCT06179303** · PHASE2 · RECRUITING · sponsor: **University of Washington** · enrollment: 60 (estimated)

## Conditions studied

- Anatomic Stage III Breast Cancer AJCC v8
- Anatomic Stage IV Breast Cancer AJCC v8
- Locally Advanced Unresectable HER2-Negative Breast Carcinoma
- Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma
- Metastatic HER2-Negative Breast Carcinoma
- Metastatic Hormone Receptor-Positive Breast Carcinoma

## Interventions

- **DRUG:** Abemaciclib
- **DRUG:** Anastrozole
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Diagnostic Imaging Testing
- **DRUG:** Exemestane
- **OTHER:** Fludeoxyglucose F-18
- **DRUG:** Fluorine F 18 Fluoro Furanyl Norprogesterone
- **DRUG:** Fulvestrant
- **BIOLOGICAL:** Gonadotropin-releasing Hormone Analog
- **DRUG:** Letrozole
- **PROCEDURE:** Positron Emission Tomography
- **DRUG:** Tamoxifen
- **DRUG:** Therapeutic Estradiol

## Key facts

- **NCT ID:** NCT06179303
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-22
- **Primary completion:** 2027-03-01
- **Final completion:** 2028-06-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-16

## Collaborators

- Breast Cancer Research Foundation

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06179303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06179303, "Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06179303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*